Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

Pfizer’s financial ... value for the company. This analysis is based on information available up to June 14, 2025, and reflects the market conditions and company performance known at that ...

the stock appears undervalued based on its Fair Value estimates, suggesting potential upside for investors. This comprehensive analysis examines Pfizer’s current position, recent performance ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Pfizer offers a high 7.4% dividend yield and trades at low valuation multiples. Click here to read more about PFE stock and ...

Pfizer (NYSE:PFE) announced robust sales for the antifungal drug Cresemba in partnership with Basilea Pharmaceutica Ltd, ...

Despite recent underperformance, a "Buy" rating on Pfizer ... analysis of this type of information. Analyst’s Disclosure:I/we have a beneficial long position in the shares of PFE either through ...

To watch more expert insights and analysis on the latest market action ... Wall Street analysts remain highly optimistic about the stock’s future potential. Despite Cincinnati Financial's strong ...

ANGLE presents new data at EACR 2025 DEMONSTRATING DNA DUAL ANALYSIS FOR COMPREHENSIVE LIQUID BIOPSY PROFILINGPoster highlights ANGLE's combined CTC-DNA and ctDNA analysis revealing tumour ...

This analysis is based on information available up to June 14, 2025, and reflects the market conditions and company performance known at that time. InvestingPro has identified several key strengths ...